NASDAQ : UPB

Upstream Bio, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.27 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 179.10M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Details

NameUpstream Bio, Inc.
SectorHealthcare
IndustryBiotechnology
Employees75
Founded2021
Ipo Date2024-10-11
CeoE. Sutherland
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price17.00
IsinUS91678A1079
Cusip91678A107
Cik2022626
Sic2834

Key executives

NameTitle
Dr. E. Rand Sutherland M.D., M.P.H.Chief Executive Officer and Director
Michael Paul Gray CPA, MBAChief Financial Officer and Chief Operating Officer
Aaron Deykin M.D.Chief Medical Officer and Head of Research and Development
Stacy Price M.S., P.M.P.Chief Technology Officer
Meggan BuckwellDirector of Corporate Communications and Investor Relations
Allison C. Ambrose J.D.Senior Vice President, General Counsel and Secretary
Lisa FieringSenior Vice President of People and Culture
Dr. Adam Houghton M.B.A., Ph.D.Chief Business Officer
Mersedeh Miraliakbari Pharm.D.Senior Vice President of Regulatory Affairs and Quality
Fang Xie Ph.D.Vice President and Head of Biometrics

Contact

Address890 Winter Street, Suite 200, Waltham, Massachusetts 02451, United States
Phone781 208 2466
Websitehttps://upstreambio.com